Autolus Therapeutics Announces Pivotal Phase 2 FELIX Trial of…

Autolus Therapeutics Announces Pivotal Phase 2 FELIX Trial of…

Facebook
Twitter
LinkedIn

LONDON, April 27, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc AUTHa clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies, today announced that the summary of the pivotal Phase 2 FELIX study of obecabtagene-autoleucel (Obe-Cel) in relapsed/refractory ( r/r) adult B-cell acute lymphoblastic leukemia (ALL) has been selected for an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6, 2023 in Chicago.

ASCO Oral Presentation, Abstract #7000:

Title: Safety and Efficacy of Obecabtagene Autoleucel (Obe-Cel, AUTO1), a Fast-Off-Rate CD19CAR in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) in Adults: Top-Line Results of the Pivotal FELIX -Study

Session title: Hematological malignancies – leukemia, myelodysplastic syndromes and allotransplantation

Session date and time: Friday, June 2, 2023, 2:00 PM – 5:00 PM EDT, 7:00 PM – 10:00 PM BST

Presenting Author: dr Claire Roddie, MD, PhD, FRCPath, Consultant Haematologist and Honorary Senior Lecturer, Cancer Institute, University College London (UCL)

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. Using a broad range of proprietary and modular T-cell programming technologies, the company develops precisely targeted, controlled and highly active T-cell therapies designed to better recognize cancer cells, disrupt their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematologic malignancies and solid tumors. For more information, please visit www.autolus.com.

About obe-cel (AUTO1)
Obe-cel is an investigational CD19 CAR T cell therapy designed to overcome limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Designed to have a fast target lock-off rate to…



Source story

More to explorer